Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRITACE: TACE with irinotecan + mitomycin C versus TACE with doxorubicin in hepatocellular carcinoma
2019-000922-23Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jan 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing TACE with irinotecan + mitomycin C with TACE with doxorubicin (2 arms). Primary endpoint: Progression-free survival. Started Jan 2020; status: completed.
02
Drugs
irinotecanmitomycin cdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-000922-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000922-23.